{"organizations": [], "uuid": "a3958932eae2c120cd8e17b0b2aad7ffa866c8b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180413.html", "section_title": "Archive News &amp; Video for Friday, 13 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-kalytera-terminates-pre-clinical-p/brief-kalytera-terminates-pre-clinical-programs-in-bone-disease-idUSFWN1RQ0K0", "country": "US", "domain_rank": 408, "title": "BRIEF-Kalytera Terminates Pre Clinical Programs In Bone Disease", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-13T21:06:00.000+03:00", "replies_count": 0, "uuid": "a3958932eae2c120cd8e17b0b2aad7ffa866c8b3"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-kalytera-terminates-pre-clinical-p/brief-kalytera-terminates-pre-clinical-programs-in-bone-disease-idUSFWN1RQ0K0", "ord_in_thread": 0, "title": "BRIEF-Kalytera Terminates Pre Clinical Programs In Bone Disease", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "kalytera therapeutics inc", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "April 13 (Reuters) - Kalytera Therapeutics Inc:\n* COMPANY TO FOCUS RESOURCES ON GVHD AND PAIN PROGRAMS * DETERMINED INVESTMENTS OF TIME, RESOURCES IN THESE PROGRAMS NOT APPROPRIATE GIVEN OTHER OPPORTUNITIES IN DEVELOPMENT PIPELINE\n* TERMINATED PROGRAMS WERE EVALUATING THREE SYNTHETIC ENDOCANNABINOID COMPOUNDS, KAL436, KAL439 AND KAL671\n* CLINICAL PROGRAMS DOES NOT REFLECT A NEGATIVE ASSESSMENT OF COMPOUNDS LICENSED FROM YISSUM\n* DECISION TO TERMINATE THESE PROGRAMS IS PART OF OVERALL STRATEGY TO FOCUS ON DEVELOPMENT OF CANNABINOID THERAPEUTICS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-04-13T21:06:00.000+03:00", "crawled": "2018-04-14T13:26:20.004+03:00", "highlightTitle": ""}